Brief: Maxcyte Says Enters Strategic Platform License With TG Therapeutics
12/02/2025 07:18
Feb 12 (Reuters) - MaxCyte Inc MXCT.O :
* MAXCYTE, INC. MAXCYTE, INC. - MXCR - STRATEGIC PLATFORM
LICENSE
WITH TG THERAPEUTICS
* MAXCYTE INC - ENTERS STRATEGIC PLATFORM LICENSE WITH TG
THERAPEUTICS
* MAXCYTE INC - TG THERAPEUTICS OBTAINS RIGHTS TO USE
MAXCYTE
TECHNOLOGY
Source text: ID:nRSL7610Wa
Further company coverage: MXCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsCell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted
Brief: MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
MaxCyte Inc reports results for the quarter ended June 30 - Earnings Summary
MaxCyte Q2 revenue beats estimates
MaxCyte Inc expected to post a loss of 9 cents a share - Earnings Preview